Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer

Liu, Wenwen; Li, Yang; Zhang, Yan; Shen, Xianjuan; Su, Zhangyao; Chen, Lin; Cai, Wei; Wang, Rui; Ju, Shaoqing

doi:10.1016/j.prp.2019.152757

Cited by 13 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28,29 Moreover, it also plays as an effective diagnostic and poor prognostic target in poor prognosis. 30,31 In the present work, our findings suggested that lncRNA FEZF1-AS1 expression was much higher in MM patients and cell lines, and its downregulation dramatically repressed tumor growth in vivo but stimulated apoptosis in vitro. Importantly, the similar findings were also supported by Li et al 32 Therefore, we deduced that lncRNA FEZF1-AS1 might be a candidate therapeutic targets in MM.…”

Section: Discussionsupporting

confidence: 58%

LncRNA FEZF1‐AS1 accelerates multiple myeloma progression by regulating IGF2BP1/BZW2 signaling

Long

Wen

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second largest hematological tumor with clonal proliferation of malignant plasma cells. Growing reports have revealed that the dysregulation of long non‐coding RNA (lncRNA) is involved in the MM progression. Nevertheless, lncRNA FEZF1 antisense RNA 1 (FEZF1‐AS1) remain not deeply explored. The RNA transcripts and protein level of MM‐associated molecule were measured by quantitative real‐time polymerase chain reaction or western blot assays, respectively. The clinical correlation was analyzed by Pearson analysis. Molecular interactions among lncRNA FEZF1‐AS1, basic leucine zipper and W2 domain 2 (BZW2) and insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1) were verified by RNA immunoprecipitation and RNA pull‐down assays. The survival of MM cells was detected by cell counting kit‐8 and flow cytometry assays. Xenograft tumor in vivo was performed to assess tumor growth. The RNA transcripts of lncRNA FEZF1‐AS1, BZW2 and IGF2BP1 were upregulated in MM samples compared to those in healthy donors. Knockdown of lncRNA FEZF1‐AS1 could inhibit the proliferation and induce cell apoptosis in vitro and in vivo. Besides, lncRNA FEZF1‐AS1 could maintain the stability of BZW2 mRNA by interacting IGF2BP1. Moreover, BZW2 silence also downregulated the proliferation but enhanced apoptosis of MM cells, while BZW2 overexpression had an opposite role, which dramatically reversed the regulatory roles of lncRNA FEZF1‐AS1. Altogether, lncRNA FEZF1‐AS1 facilitated MM development by regulating IGF2BP1/BZW2 signaling, suggesting that lncRNA FEZF1‐AS1 might be a candidate for MM treatment.

show abstract

Section: Discussionsupporting

confidence: 58%

LncRNA FEZF1‐AS1 accelerates multiple myeloma progression by regulating IGF2BP1/BZW2 signaling

Long

Wen

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…The combination of FEZF1-AS1 and AFAP1-AS1 increases the AUC value to 0.866, whereas the combination of FEZF1-AS1, AFAP1-AS1, CEA, and CA19-9 increases the diagnostic sensitivity to 95.5%. 175 …”

Section: Clinical Implications Of Lncrnas In Gcmentioning

confidence: 99%

Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer

Liu

Ding

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the most prevalent malignant tumor types and the third leading cause of cancer-related death worldwide. Its morbidity and mortality are very high due to a lack of understanding about its pathogenesis and the slow development of novel therapeutic strategies. Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs with a length of more than 200 nt. They play crucial roles in a wide spectrum of physiological and pathological processes by regulating the expression of genes involved in proliferation, differentiation, apoptosis, cell cycle, invasion, metastasis, DNA damage, and carcinogenesis. The aberrant expression of lncRNAs has been found in various cancer types. A growing amount of evidence demonstrates that lncRNAs are involved in many aspects of GC pathogenesis, including its occurrence, metastasis, and recurrence, indicating their potential role as novel biomarkers in the diagnosis, prognosis, and therapeutic targets of GC. This review systematically summarizes the biogenesis, biological properties, and functions of lncRNAs and highlights their critical role and clinical significance in GC. This information may contribute to the development of better diagnostics and treatments for GC.

show abstract

“…In addition to the significant increase in the expression of AFAP1-AS1 in various solid tumor tissues, which can be used as a molecular marker for predicting the efficacy of therapy and prognosis of patients, several groups have reported the expression of AFAP1-AS1 in peripheral blood samples of patients with nasopharyngeal cancer (He et al, 2017), lung cancer (Li et al, 2017), and gastric cancer (Liu et al, 2020), with no detection of AFAP1-AS1 in peripheral blood samples of normal control populations. These findings support the expectation that AFAP1-AS1 could be a serum marker of malignant tumors and may serve as an early diagnosis biomarker of these cancers.…”

Section: Afap1-as1 Is Upregulated In Various Tumor Tissues and Is A New Tumor Molecular Markermentioning

confidence: 99%

“…Therefore, AFAP1-AS1 is not only a molecular marker for cancer diagnosis but also a new target for tumor treatment. AFAP1-AS1 expression is upregulated in peripheral blood samples from patients with nasopharyngeal cancer (He et al, 2017), lung cancer , and gastric cancer (Liu et al, 2020). However, its value as a new biomarker for liquid biopsy (Ye et al, 2019) of malignant tumors has yet to be verified with a large number of clinic samples.…”

Section: Summary and Future Perspectivesmentioning

confidence: 99%

AFAP1-AS1: a rising star among oncogenic long non-coding RNAs

Xiong

Deng

Huang

et al. 2021

Sci. China Life Sci.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have become a hotspot in biomedical research. This interest reflects their extensive involvement in the regulation of the expression of other genes, and their influence on the occurrence and development of a variety of human diseases. Actin filament associated protein 1-Antisense RNA 1(AFAP1-AS1) is a recently discovered oncogenic lncRNA. It is highly expressed in a variety of solid tumors, and regulates the expression of downstream genes and signaling pathways through adsorption and competing microRNAs, or by the direct binding to other proteins. Ultimately, AFAP1-AS1 promotes proliferation, chemotherapy resistance, and resistance to apoptosis, maintains stemness, and enhances invasion and migration of tumor cells. This paper summarizes the research concerning AFAP1-AS1 in malignant tumors, including the clinical application prospects of AFAP1-AS1 as a potential molecular marker and therapeutic target of malignant tumors. We also discuss the limitations in the knowledge of AFAP1-AS1 and directions of further research. AFAP1-AS1 is expected to provide an example for studies of other lncRNA molecules.

show abstract

Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer

Cited by 13 publications

References 27 publications

LncRNA FEZF1‐AS1 accelerates multiple myeloma progression by regulating IGF2BP1/BZW2 signaling

LncRNA FEZF1‐AS1 accelerates multiple myeloma progression by regulating IGF2BP1/BZW2 signaling

Long non-coding RNAs: Biogenesis, functions, and clinical significance in gastric cancer

AFAP1-AS1: a rising star among oncogenic long non-coding RNAs

Contact Info

Product

Resources

About